Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Cboe UK GBp

AstraZeneca PLC (AZNL.XC)

Compare
11,838.00
-160.00
(-1.33%)
As of 12:54:21 PM GMT. Market Open.
Loading Chart for AZNL.XC
  • Previous Close 11,998.00
  • Open 12,074.00
  • Bid 11,844.00 x --
  • Ask 11,846.00 x --
  • Day's Range 11,784.00 - 12,082.00
  • 52 Week Range 9,670.00 - 13,336.00
  • Volume 210,351
  • Avg. Volume 380,750
  • Market Cap (intraday) 183.508B
  • Beta (5Y Monthly) 0.16
  • PE Ratio (TTM) 3,411.53
  • EPS (TTM) 3.47
  • Earnings Date Apr 29, 2025
  • Forward Dividend & Yield 2.46 (2.05%)
  • Ex-Dividend Date Feb 20, 2025
  • 1y Target Est --

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

www.astrazeneca.com

94,300

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AZNL.XC

View More

Performance Overview: AZNL.XC

Trailing total returns as of 3/17/2025, which may include dividends or other distributions. Benchmark is FTSE 100 .

YTD Return

AZNL.XC
13.26%
FTSE 100
5.83%

1-Year Return

AZNL.XC
14.98%
FTSE 100
11.94%

3-Year Return

AZNL.XC
24.13%
FTSE 100
17.12%

5-Year Return

AZNL.XC
76.05%
FTSE 100
63.36%

Compare To: AZNL.XC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AZNL.XC

View More

Valuation Measures

Annual
As of 3/14/2025
  • Market Cap

    185.93B

  • Enterprise Value

    204.91B

  • Trailing P/E

    34.54

  • Forward P/E

    17.48

  • PEG Ratio (5yr expected)

    0.93

  • Price/Sales (ttm)

    4.49

  • Price/Book (mrq)

    6.16

  • Enterprise Value/Revenue

    4.91

  • Enterprise Value/EBITDA

    17.20

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.01%

  • Return on Assets (ttm)

    7.88%

  • Return on Equity (ttm)

    17.59%

  • Revenue (ttm)

    54.07B

  • Net Income Avi to Common (ttm)

    7.03B

  • Diluted EPS (ttm)

    3.47

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.53B

  • Total Debt/Equity (mrq)

    74.53%

  • Levered Free Cash Flow (ttm)

    8.46B

Research Analysis: AZNL.XC

View More

Company Insights: AZNL.XC

Research Reports: AZNL.XC

View More

People Also Watch